Skip to content

Fructus Mume Pill in the treatment of type 2 diabetes: a randomised controlled pilot trial

Traditional Chinese Medicinal herbs of cold and hot properties in the treatment of type 2 diabetes: a randomised controlled pilot trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-12002320
Enrollment
Unknown
Registered
2012-02-13
Start date
2011-05-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

Fructus Mume Pill group:Fructus Mume Pill

Sponsors

Teaching Hospital of Chengdu University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Type 2 diabetes mellitus and 7.0mmol/l(126mg/dl) <=fasting plasma glucose (FPG)<=13.3 mmol/l(240mg/dl) or 1.1mmol/l (200mg/dl) <=2h postprandial plasma glucose(2hPG)<=22.9mmol/l (412mg/dl); 3. an age of 18 to 70 years; 3. normal renal function and the value of transaminase was lower than one and a half time of the upper limit; 4. those who were taking hypoglycemia agents could undergo a one-week washout period and could undergo randomization if their blood glucose levels meet our inclusion criteria; 5. provide the written consent form.

Exclusion criteria

Exclusion criteria: 1. pregnancy or lactation; 2. a history of alcohol abuse; 3. a history of cerebrovascular accident, malignant hypertension and acute coronary syndrome within the previous six months; 4. allergic constitution or an allergic history to TCM; 5. had taken medications which are known to affect glucose metabolism, such as thiazide diuretic, nicotinic acid, etc within the past three months; 6. had comorbidity such as chronic heart failure, chronic renal failure, hematopoietic system disease, mental disorders; 7. had diseases which are known to affect glucose metabolism such as thyroid disease and adrenal gland disease; 8. had participated in other clinical trials within the past three months.

Design outcomes

Primary

MeasureTime frame
Fasting plasma glucos;

Secondary

MeasureTime frame
postprandial plasma glucose;HbA1c;Lipid profiles;insulin concentration;Body Mass Index;

Countries

China

Contacts

Public ContactSen Zhong
zhongsen6606@163.com+86 18980086606

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026